(CIDRAP News) A new facility built in England to produce MedImmune's intranasal flu vaccine, FluMist, has gained the US Food and Drug Administration's approval, the company announced last week.
The facility in Liverpool will increase the company's production capacity to about 90 million bulk doses per season, MedImmune said in a news release.